BTK and atrial fibrillation: Early results of a newer, more selective BTK inhibitor, acalabrutinib, suggest that this agent may be devoid of many of the potentially serious toxicities associated with ibrutinib, including hemorrhage and AF.63 These features are especially valuable in a population that includes a large proportion of older and, at times, frail patients.